克唑替尼联合AP化疗方案治疗晚期非小细胞肺癌患者的效果

Effects of Crizotinib combined with AP chemotherapy in treatment of patients with advanced non-small cell lung cancer

目的:观察克唑替尼联合AP化疗方案治疗晚期非小细胞肺癌患者的效果。方法:选取2022年1月至2023年8月该院收治的80例晚期非小细胞肺癌患者进行前瞻性研究,按照随机数字表法将其分为对照组(n=40)和研究组(n=40)。对照组采用AP化疗方案治疗,研究组在对照组基础上采用克唑替尼靶向治疗,比较两组临床疗效,治疗前后血清肿瘤标志物[癌胚抗原(CEA)、组织多肽抗原(TPA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白片段19抗原21-1(CRYFRA21-1)]水平,以及不良反应发生率。结果:研究组客观缓解率为82.50%(33/40),高于对照组的62.50%(25/40),差异有统计学意义(P<0.05);治疗后,两组CEA、TPA、NSE、CRYFRA21-1水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:克唑替尼联合AP化疗方案治疗晚期非小细胞肺癌患者可提高客观缓解率,降低血清肿瘤标志物水平,其效果优于单纯AP化疗方案治疗。

Objective:To observe effects of Crizotinib combined with AP chemotherapy in treatment of patients with advanced non-small cell lung cancer.Methods:A prospective study was conducted on 80 patients with advanced non-small cell lung cancer admitted to the hospital from January 2022 to August 2023.According to the random number table method,they were divided into control group(n=40)and study group(n=40).The control group was treated with AP chemotherapy regimen,while the study group was treated with Crizotinib targeted therapy on the basis of that of the control group.The clinical efficacy,the serum tumor markers[carcinoembryonic antigen(CEA),tissue polypeptide antigen(TPA),neuron-specific enolase(NSE),cytokeratin fragment 19 antigen 21-1(CRYFRA21-1)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the study group was 82.50%(33/40),which was higher than 62.50%(25/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,TPA,NSE and CRYFRA21-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Crizotinib combined with AP chemotherapy in the treatment of the patients with advanced non-small cell lung cancer can improve the objective remission rate and reduce the levels of serum tumor markers.Moreover,it is superior to simple AP chemotherapy regimen.